Company Expands Product Portfolio, Enters $10b+ Global Market For Mind, Memory and Mood Enhancers
Ongoing research suggests that nootropics may also play a role in mental health. According to the
Market research estimates global nootropic sales exceeded
On a cellular level, this benefit is supported by increased mitochondrial energy production, especially within the nervous, cardiovascular, and muscular systems.
Consumers, including Seniors with or without cognitive issues, as well as, e-Gamers and those engaged in activities requiring prolonged periods of focus and intense concentration, report that the ingredients in MindnMemory help them achieve clear thinking, focus, more rapid recall, a sense of well-being, and resistance to mental and physical fatigue. We are encouraged by the early success of MindnMemory to expand our development of more innovative formulations to further benefit mental functionality. “
About
The Company’s current dietary supplement formulations are carefully selected from the best worldwide sources and utilize proprietary methods of enhancing the bioavailability of nutrients. The products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as providing improvements in appearance. Our current product line includes PrimiLungs™ and PluriPain® for humans and Equine All-in-One™ for horses.
Additional human products, to be introduced soon, are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; and improve overall emotional and physical wellness. BioAdaptives’ common shares trade in the OTC market under the symbol BDPT. It has over 13,000 current shareholders. None of the statements about the Company’s products have been approved by the
Additional information can be found at www.shopbioadaptives.com or in our
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the
Contact:
Investor Relations
(702) 659-8829
info@bioadaptives.com
Source:
2022 GlobeNewswire, Inc., source